ANALYSIS: Will Sun-Ranbaxy Pairing Trigger More M&As In India?
This article was originally published in PharmAsia News
Executive Summary
The Indian pharmaceutical market is seeing a decisive shift. Starting now, Sun and Ranbaxy as a combined organization will dislodge Abbott from its top position held for over five years. Will companies respond with more merger deals or stay with incremental organic growth?